menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Adopting the New Therapeutic “LineUp” to Manage ASCVD - East

Join expert faculty to ensure you’re appropriately managing the care of your patients with ASCVD.

Live Meeting
3.50 available credits
Information
February 04, 2022
07:45 AM - 12:00 PM EST
Hyatt Regency Sarasota
1000 Boulevard of the Arts, Sarasota, Florida, United States
Hyatt Regency Sarasota
ReachMD Healthcare Image
Choose a format
Details
Presenters
Related
Comments
  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

    Click Here to Download Slide Presentation

  • Program Schedule*

    Click Here to Download Slide Presentation

    7:45 am–8:30 am

    Registration and Breakfast

    8:30 am–8:35 am

    Welcome, Introductions, Program Overview
    Michael Miller, MD
    Program Chair

    8:35 am–8:45 am

    Burden of Heart Disease Today
    James Underberg, MD

    8:45 am–9:15 am

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Aruna Pradhan, MD

    9:15 am–9:45 am

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Michael Miller, MD

    9:45 am–10:00 am

    Panel Discussion
    All faculty

    10:00 am–10:15 am

    Break

    10:15 am–10:30 am

    Recent Evidence from REDUCE-IT Sub-studies
    Michael Miller, MD

    10:30 am–11:00 am

    Differential Biological Effects of Omega-3 Fatty Acids
    James Underberg, MD

    11:00 am–11:20 am

    Role of Pharmacist in Establishing Lipid Intervention
    Mary Katherine Cheeley, PharmD

    11:20 am–11:35 am

    11:35 am–11:55 am

    Panel Discussion
    All Faculty

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    11:55 am–12:00 pm   

    Closing Comments, Adjourn
    Michael Miller, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:

    Michael Miller, MD, FACC, FAHA
    Chief of Medicine
    Corporal Michael J. Crescenz VAMC; 
    Professor and Vice Chair of Medicine
    University of Pennsylvania School of Medicine
    Philadelphia, PA
    Consulting Fees: Amarin, Pfizer, 89Bio

    Faculty:

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Clinical Pharmacist Specialist, Primary Care
    Grady Health System
    Atlanta, GA
    No relationship reported

    Aruna Pradhan, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School;
    Associate Physician
    Scientific Director, Preventive Medicine Cohorts Biorepository
    Division of Preventive Medicine
    Brigham and Women's Hospital
    Boston, MA
    Consulting Fees: Novo Nordisk
    Contracted Research: Kowa Research Institute

    James Underberg, MD, MS, FACP, FNLA
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine
    NYU Center for Prevention of Cardiovascular Disease;
    Director, Bellevue Hospital Lipid Clinic;
    Past President, National Lipid Association
    New York, NY
    Consulting Fees:  Amgen, Esperion, Novartis
    Speakers Bureau: Alexion, Amarin, Amgen, Amyrt Pharma, Esperion
    Contracted Research: Amyrt Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided. 

    Click Here to Download Slide Presentation

  • Program Schedule*

    Click Here to Download Slide Presentation

    7:45 am–8:30 am

    Registration and Breakfast

    8:30 am–8:35 am

    Welcome, Introductions, Program Overview
    Michael Miller, MD
    Program Chair

    8:35 am–8:45 am

    Burden of Heart Disease Today
    James Underberg, MD

    8:45 am–9:15 am

    Atherogenic Dyslipidemia and New Approaches to Risk Assessment for ASCVD
    Aruna Pradhan, MD

    9:15 am–9:45 am

    REDUCE-IT Clinical Trials and Omega 3 Fatty Acids for ASCVD Risk Reductions
    Michael Miller, MD

    9:45 am–10:00 am

    Panel Discussion
    All faculty

    10:00 am–10:15 am

    Break

    10:15 am–10:30 am

    Recent Evidence from REDUCE-IT Sub-studies
    Michael Miller, MD

    10:30 am–11:00 am

    Differential Biological Effects of Omega-3 Fatty Acids
    James Underberg, MD

    11:00 am–11:20 am

    Role of Pharmacist in Establishing Lipid Intervention
    Mary Katherine Cheeley, PharmD

    11:20 am–11:35 am

    11:35 am–11:55 am

    Panel Discussion
    All Faculty

    Clinical Approaches to Personalizing Medical Management of ASCVD Risk Factors
    All Faculty

    11:55 am–12:00 pm   

    Closing Comments, Adjourn
    Michael Miller, MD

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:

    Michael Miller, MD, FACC, FAHA
    Chief of Medicine
    Corporal Michael J. Crescenz VAMC; 
    Professor and Vice Chair of Medicine
    University of Pennsylvania School of Medicine
    Philadelphia, PA
    Consulting Fees: Amarin, Pfizer, 89Bio

    Faculty:

    Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
    Clinical Pharmacist Specialist, Primary Care
    Grady Health System
    Atlanta, GA
    No relationship reported

    Aruna Pradhan, MD, MPH
    Assistant Professor of Medicine
    Harvard Medical School;
    Associate Physician
    Scientific Director, Preventive Medicine Cohorts Biorepository
    Division of Preventive Medicine
    Brigham and Women's Hospital
    Boston, MA
    Consulting Fees: Novo Nordisk
    Contracted Research: Kowa Research Institute

    James Underberg, MD, MS, FACP, FNLA
    Clinical Lipidology
    Clinical Assistant Professor of Medicine
    NYU School of Medicine
    NYU Center for Prevention of Cardiovascular Disease;
    Director, Bellevue Hospital Lipid Clinic;
    Past President, National Lipid Association
    New York, NY
    Consulting Fees:  Amgen, Esperion, Novartis
    Speakers Bureau: Alexion, Amarin, Amgen, Amyrt Pharma, Esperion
    Contracted Research: Amyrt Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Cindy Davidson has nothing to disclose. 
    • Kate Nagele has nothing to disclose.
    • Mario Trucillo, PhD, MS has nothing to disclose.
    • Kathy Wickman has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Understand the key findings of large-scale omega-3 fatty acid clinical trials and how this information relates to reducing ASCVD events in clinical practice
    • Apply recent clinical trial evidence of EPA on a case-by-case basis for patients with established CVD who are on statins and at risk of further CV events
    • Identify barriers to the implementation of effective, long-term management of ASCVD
  • Target Audience

    This activity is designed to meet the educational needs of primary care physicians and community pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Kate Nagele prior to the live event at knagele@glc.healthcare.

Facebook Comments

Schedule15 Aug 2022
Webpack App